CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetesJuly 16, 2019Diabetes
The costs and benefits of SGLT2 inhibitors & GLP-1 RAsJuly 15, 2019DiabetesPituitary, Thyroid & Adrenal DisordersObesityBusiness of Medicine
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adultsJuly 12, 2019DiabetesObesityLipid Disorders
Microvascular disease: An independent and exacerbating risk factor for amputationJuly 8, 2019Diabetes
Mortality caused by chronic liver disease in setting of diabetes continues to riseJuly 5, 2019Diabetes
CAROLINA findings reaffirm linagliptin’s safety, free glimepiride of CV-risk stigmaJuly 1, 2019Diabetes
To help patients stay on diabetes regimens: Communicate, educate, and use technologyJuly 1, 2019Diabetes
